Organization Profile

You just read:

Taiho Oncology's TAS-102 Meets Primary Endpoint of Improving Overall Survival in Global Phase III RECOURSE Trial in Refractory Metastatic Colorectal Cancer

News provided by

Taiho Pharmaceutical Co., Ltd.

May 12, 2014, 04:02 ET